Plain-English answer
The biggest mistake U.S. healthcare companies make in China is confusing interest with access. A Chinese physician, distributor, investor, or hospital may express enthusiasm, but that does not mean the product has the right regulatory route, reimbursement evidence, procurement pathway, compliant data model, or price. China is attractive precisely because it is large and sophisticated; it is risky for the same reason.
Market context
U.S. companies often enter with assumptions formed in FDA, Medicare, commercial payer, or U.S. hospital environments. China has different institutional actors. NMPA controls product approval, NHSA controls much of reimbursement economics, public hospitals concentrate demand, procurement platforms shape price, and data rules can constrain digital products. The sequence of decisions is different.
Policy changes are frequent enough that stale assumptions are dangerous. NRDL negotiations, VBP expansion, cross-border data flow rules, wholly foreign-owned hospital pilots, public hospital reform, and anti-corruption campaigns can all change the attractiveness of a business model.
Operating model
Common mistakes include relying on a distributor before regulatory strategy is clear; assuming NMPA approval creates reimbursement; ignoring hospital procurement committees; using U.S. evidence without China-specific comparator analysis; underestimating price pressure; collecting patient data before compliance review; giving partners uncontrolled access to IP or customer accounts; and treating all tertiary hospitals as equivalent.
Another mistake is over-localizing too early. Local manufacturing, licensing, or a JV may be useful, but not before the company knows which function needs localization. A local entity cannot fix a product that lacks evidence or a price model that will collapse under procurement.
Strategic reading
A better approach is to build a staged China plan with kill criteria. First classify the product and test regulatory feasibility. Then test payer and procurement exposure. Then choose pilot sites and partners. Then localize only the capabilities that solve a real barrier. At each stage, the company should be willing to stop if the economics, compliance, or control risks are unacceptable.
China rewards companies that respect institutional detail. It punishes companies that chase the size of the market without understanding who can approve, pay, buy, use, and govern the product.
Implementation detail
Another frequent mistake is treating China as either impossible or automatic. Both views are lazy. The real work is category-specific: a commodity generic, rare-disease drug, surgical robot accessory, AI imaging model, private hospital service, and academic research project face different risks. A company should not generalize from one China anecdote to another product type.
U.S. firms also underestimate internal coordination. China decisions affect regulatory, legal, privacy, quality, pricing, medical affairs, finance, tax, supply chain, and global commercial strategy. If the China team is left alone to negotiate with partners, it may solve local access by creating global exposure.
Decision test
For Common Mistakes U.S. Healthcare Companies Make in China, the practical test is whether the company can name the exact authority, budget holder, data owner, hospital user, and compliance control that must act next. If the answer is only a broad market statement, the plan is not ready. A serious China plan should identify the next filing, negotiation, tender, hospital committee, data review, partner obligation, or evidence milestone and explain what would make the company stop, revise, or scale.